Published in Clin Cancer Res on September 14, 2011
Combination strategies to enhance antitumor ADCC. Immunotherapy (2012) 1.12
Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunol Cell Biol (2017) 1.05
Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytes. PLoS One (2013) 1.00
Augmentation of antitumor immunity by fusions of ethanol-treated tumor cells and dendritic cells stimulated via dual TLRs through TGF-β1 blockade and IL-12p70 production. PLoS One (2013) 0.87
Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant. Immunobiology (2013) 0.81
VEGFR2 targeted antibody fused with MICA stimulates NKG2D mediated immunosurveillance and exhibits potent anti-tumor activity against breast cancer. Oncotarget (2016) 0.79
Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. Oncoimmunology (2015) 0.76
Protein-bound polysaccharide-K induces IL-1β via TLR2 and NLRP3 inflammasome activation. Innate Immun (2013) 0.76
Complete Spontaneous Regression of Merkel Cell Carcinoma Metastatic to the Liver: Did Lifestyle Modifications and Dietary Supplements Play a Role? Glob Adv Health Med (2012) 0.75
Maturation of morphology, phenotype and functions of murine bone marrow-derived dendritic cells (DCs) induced by polysaccharide Kureha (PSK). Hum Vaccin Immunother (2012) 0.75
Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK. Cancer Immunol Immunother (2013) 0.75
Immune Modulation From Five Major Mushrooms: Application to Integrative Oncology. Integr Med (Encinitas) (2014) 0.75
Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth. Oncotarget (2016) 0.75
Preoperative administration of polysaccharide Kureha and reduced plasma transforming growth factor-β in patients with advanced gastric cancer: A randomized clinical trial. Mol Clin Oncol (2015) 0.75
Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis. Oncoimmunology (2017) 0.75
NK cell recognition. Annu Rev Immunol (2005) 14.40
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med (2000) 13.24
Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med (2007) 12.73
Human natural killer cells. Blood (2008) 7.37
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol (2008) 6.90
CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods (2004) 6.89
Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood (2001) 5.23
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer (2006) 2.75
Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia (1994) 2.65
APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA. J Immunol (2004) 2.65
Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol (2004) 2.44
Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A (2011) 2.35
CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci U S A (2004) 2.23
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol (2010) 2.12
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet (1994) 2.06
Toll-like receptor polymorphisms and susceptibility to human disease. Clin Sci (Lond) (2008) 1.94
Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res (2007) 1.88
TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol (2005) 1.83
An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry. J Immunol Methods (1994) 1.76
IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest (2002) 1.74
The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res (2007) 1.66
Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol (2006) 1.65
Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist (2006) 1.65
Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol (2006) 1.58
NK cells and cancer. J Immunol (2007) 1.56
Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res (2004) 1.49
Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists. Int Immunol (2006) 1.31
Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol (2010) 1.26
IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production. J Immunol (2011) 1.25
The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Cancer Res (2006) 1.22
Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection. PLoS Pathog (2010) 1.22
Human NK cells directly recognize Mycobacterium bovis via TLR2 and acquire the ability to kill monocyte-derived DC. Int Immunol (2008) 1.20
Identification of a polyI:C-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activation. J Exp Med (2010) 1.20
Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Res (2010) 1.20
CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol (2005) 1.15
Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res (2002) 1.14
Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer (2004) 1.13
Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res (2002) 1.12
Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunol Immunother (2006) 1.09
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol (2009) 1.07
Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother (2005) 0.96
Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy. Clin Cancer Res (2010) 0.96
NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. Exp Hematol (2007) 0.94
Impaired natural killer cell lysis in breast cancer patients with high levels of psychological stress is associated with altered expression of killer immunoglobin-like receptors. J Surg Res (2007) 0.93
Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC). Cancer Lett (2008) 0.87
Human breast cancer and impaired NK cell function. J Surg Oncol (1983) 0.87
The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation. PLoS One (2010) 0.86
Effect of krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer. Anticancer Res (1994) 0.85
Activation of human natural killer cells by the protein-bound polysaccharide PSK independently of interferon and interleukin 2. Immunol Lett (1992) 0.82
Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med (2013) 24.88
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Regulators of PP2C phosphatase activity function as abscisic acid sensors. Science (2009) 8.84
A validated regulatory network for Th17 cell specification. Cell (2012) 4.82
Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature (2011) 4.56
Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells. J Exp Med (2012) 2.97
Spatiotemporal control of gene expression by a light-switchable transgene system. Nat Methods (2012) 2.79
Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev (2006) 2.77
High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods (2009) 2.75
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol (2011) 2.52
Relay and control of abscisic acid signaling. Curr Opin Plant Biol (2003) 2.51
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Ryanodine receptor phosphorylation by calcium/calmodulin-dependent protein kinase II promotes life-threatening ventricular arrhythmias in mice with heart failure. Circulation (2010) 2.32
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol (2005) 2.31
Kinetics of FKBP12.6 binding to ryanodine receptors in permeabilized cardiac myocytes and effects on Ca sparks. Circ Res (2010) 2.29
Scapuloperoneal spinal muscular atrophy and CMT2C are allelic disorders caused by alterations in TRPV4. Nat Genet (2009) 2.21
Obligate ligation-gated recombination (ObLiGaRe): custom-designed nuclease-mediated targeted integration through nonhomologous end joining. Genome Res (2012) 2.12
Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J Am Diet Assoc (2003) 2.11
SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol (2011) 2.08
gp96, an endoplasmic reticulum master chaperone for integrins and Toll-like receptors, selectively regulates early T and B lymphopoiesis. Blood (2009) 2.07
Structure of the gating ring from the human large-conductance Ca(2+)-gated K(+) channel. Nature (2010) 2.00
Novel plasmid and its variant harboring both a bla(NDM-1) gene and type IV secretion system in clinical isolates of Acinetobacter lwoffii. Antimicrob Agents Chemother (2012) 1.97
Reduced mitochondrial DNA copy number is correlated with tumor progression and prognosis in Chinese breast cancer patients. IUBMB Life (2007) 1.92
Alignment of optical maps. J Comput Biol (2006) 1.88
Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med (2002) 1.85
Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus (2007) 1.78
Increased PADI4 expression in blood and tissues of patients with malignant tumors. BMC Cancer (2009) 1.78
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis. J Clin Invest (2013) 1.76
Converting ceria polyhedral nanoparticles into single-crystal nanospheres. Science (2006) 1.70
Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol (2006) 1.65
Sequence alterations within CYP7B1 implicate defective cholesterol homeostasis in motor-neuron degeneration. Am J Hum Genet (2008) 1.65
Algorithm for complementary and alternative medicine practice and research in type 2 diabetes. J Altern Complement Med (2007) 1.64
Folding of Toll-like receptors by the HSP90 paralogue gp96 requires a substrate-specific cochaperone. Nat Commun (2010) 1.62
Mapping hydration dynamics around a protein surface. Proc Natl Acad Sci U S A (2007) 1.61
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol (2008) 1.60
Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res (2008) 1.59
GPR15-mediated homing controls immune homeostasis in the large intestine mucosa. Science (2013) 1.58
Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med (2010) 1.57
Diagnosis and management of pituitary abscess: experiences from 33 cases. Clin Endocrinol (Oxf) (2011) 1.55
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol (2006) 1.53
Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res (2002) 1.51
Marked accumulation of 27-hydroxycholesterol in SPG5 patients with hereditary spastic paresis. J Lipid Res (2009) 1.50
Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res (2004) 1.49
Computer-driven automated weaning reduces weaning duration in difficult-to-wean patients. Chin Med J (Engl) (2013) 1.48
The pathogenesis and clinical significance of a high-intensity zone (HIZ) of lumbar intervertebral disc on MR imaging in the patient with discogenic low back pain. Eur Spine J (2005) 1.48
Genetically encoded fluorescent sensors for intracellular NADH detection. Cell Metab (2011) 1.47
CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother (2006) 1.47
A dammarane glycoside derived from ginsenoside Rb3. Chem Pharm Bull (Tokyo) (2005) 1.47
Targeted gene disruption by use of a group II intron (targetron) vector in Clostridium acetobutylicum. Cell Res (2007) 1.45
TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J Immunol (2006) 1.44
Identification of sequence variants in genetic disease-causing genes using targeted next-generation sequencing. PLoS One (2011) 1.44
Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res (2003) 1.42
Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity. Neuropharmacology (2007) 1.41
Environmental impact of aquaculture and countermeasures to aquaculture pollution in China. Environ Sci Pollut Res Int (2007) 1.40
Echinacea purpurea for prevention of upper respiratory tract infections in children. J Altern Complement Med (2005) 1.40
PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans. J Nucl Med (2009) 1.39
Ex vivo immunotherapy for patients with benzene-induced aplastic anemia. J Hematother Stem Cell Res (2003) 1.38
Enhanced magnetic resonance imaging of Guillain-Barré syndrome. J Paediatr Child Health (2011) 1.38
Reconstruction with modular hemipelvic prostheses for periacetabular tumor. Clin Orthop Relat Res (2007) 1.35
Possible pathogenesis of painful intervertebral disc degeneration. Spine (Phila Pa 1976) (2006) 1.35
Integrated optical coherence tomography, ultrasound and photoacoustic imaging for ovarian tissue characterization. Biomed Opt Express (2011) 1.35
Loss of miR-204 expression enhances glioma migration and stem cell-like phenotype. Cancer Res (2012) 1.33
Protein hydration dynamics and molecular mechanism of coupled water-protein fluctuations. J Am Chem Soc (2009) 1.33
Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J Clin Invest (2012) 1.32
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol (2006) 1.31
TNM staging in colorectal cancer: T is for T cell and M is for memory. J Clin Oncol (2011) 1.30
Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol Exp Ther (2007) 1.29
miR-186 downregulation correlates with poor survival in lung adenocarcinoma, where it interferes with cell-cycle regulation. Cancer Res (2012) 1.29
miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. Cancer Res (2013) 1.27
Mutation spectrum of MYO7A and evaluation of a novel nonsyndromic deafness DFNB2 allele with residual function. Hum Mutat (2008) 1.27
Divergent regulation of ryanodine receptor 2 calcium release channels by arrhythmogenic human calmodulin missense mutants. Circ Res (2014) 1.27
Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol (2010) 1.26
Myelin loss associated with neuroinflammation in hypertensive rats. Stroke (2012) 1.26
VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res (2011) 1.25
MFEprimer: multiple factor evaluation of the specificity of PCR primers. Bioinformatics (2008) 1.25
MFEprimer-2.0: a fast thermodynamics-based program for checking PCR primer specificity. Nucleic Acids Res (2012) 1.24
Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res (2008) 1.24
The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Cancer Res (2006) 1.22
The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood (2007) 1.21
CXCR3 chemokine receptor-induced chemotaxis in human airway epithelial cells: role of p38 MAPK and PI3K signaling pathways. Am J Physiol Cell Physiol (2006) 1.20
Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. Gastroenterology (2006) 1.20
Use of toxicogenomics to understand mechanisms of drug-induced hepatotoxicity during drug discovery and development. Toxicol Lett (2008) 1.20
Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Res (2010) 1.20
Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res (2003) 1.19